Mannkind Corporation (MNKD) Dividend History

Company News

• MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

  MannKind Corporation announced it will acquire scPharmaceuticals for $303 million, expanding its presence in cardiometabolic and lung diseases. The deal includes an upfront cash payment of $5.35 per share and potential additional milestone payments, representing a 36% premium to scPharmaceuticals' recent trading price.

  Benzinga

  Featured Companies: SCPH
• MannKind (MNKD) Q2 Revenue Rises 6%

  MannKind reported Q2 2025 revenue of $76.5 million, slightly missing analyst estimates. The company saw growth in Afrezza inhaled insulin sales and Tyvaso DPI royalties, while increasing R&D and marketing expenses.

  The Motley Fool

  Featured Companies: UTHR
• More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)

  A Phase 4 study found that more adults with type 1 diabetes achieved target A1C levels when switching from multiple daily injections or insulin pumps to inhaled insulin (Afrezza). The data showed continued improvement in glycemic control for those who remained on Afrezza or switched to it.

  GlobeNewswire Inc.
• MannKind Outperforms As Tyvaso DPI Captures Market Share

  MannKind's long-term liabilities exceed its assets, posing potential financial risks. Learn why MNKD stock is a Buy.

  Seeking Alpha

  Featured Companies: LQDA MRK UTHR
• MannKind (MNKD) Upgraded to Strong Buy: Here's Why

  MannKind (MNKD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

  Zacks Investment Research